AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18947426 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (maltodextrin)
Number of subjects: 120
Study 18443928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren (CDN)
Number of subjects: 1322
Study 18443928 — intervention group
Group type: COMPARATOR
Intervention: Control (penicillin V, cefuroxime, or amoxicillin/clavulanate)
Number of subjects: 1322
Study 15164512 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (600 mg daily)
Number of subjects: 2
Study 15164512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 11171786 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ramipril 10 mg/d)
Number of subjects: 35
Study 11171786 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor antagonist (losartan 100 mg/d)
Number of subjects: 35
Study 9416986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 30
Study 9416986 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 30
Study 7976112 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 16
Study 7976112 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 16
Study 7976112 — intervention group
Group type: COMPARATOR
Intervention: TI, TE, VT
Number of subjects: 16
Study 3089433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40
Study 3089433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 40
Study 3089433 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Propranolol and Pindolol
Number of subjects: 40
Study 31071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 6 strains of probiotics for 3 months
Number of subjects: 34
Study 27876806 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aspirin (ASA)
Number of subjects: 47
Study 27876806 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble tomato extract Fruitflow (FF)
Number of subjects: 47
Study 27876806 — intervention group
Group type: COMPARATOR
Intervention: Concomitant FF and ASA
Number of subjects: 47
Study 27876806 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study 25972532 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 portions of FVs daily (160 g)
Number of subjects: 92
Study 25972532 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 portions of FVs daily (320 g)
Number of subjects: 92
Study 25972532 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 portions of FVs daily (560 g)
Number of subjects: 92
Study 23525882 — intervention group
Group type: EXPERIMENTAL
Intervention: Device used group (medical ring)
Number of subjects: 37
Study 23525882 — intervention group
Group type: COMPARATOR
Intervention: Device not used group (control)
Number of subjects: 37
Study 21557791 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Valproate (VPA)
Number of subjects: 66
Study 21557791 — intervention group
Group type: COMPARATOR
Intervention: Continuous Diazepam (DZP)
Number of subjects: 66
Study 18413175 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet I (low carbohydrate)
Number of subjects: 118
Study 18413175 — intervention group
Group type: COMPARATOR
Intervention: Diet II (low fat)
Number of subjects: 118
Study 17412748 — intervention group
Group type: EXPERIMENTAL
Intervention: Car seat trial
Number of subjects: 20
Study 17412748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse observations during car seat trial
Number of subjects: 20
Study 17412748 — intervention group
Group type: COMPARATOR
Intervention: Cot
Number of subjects: 20
Study 17412748 — intervention group
Group type: COMPARATOR
Intervention: Car seat
Number of subjects: 20
Study 14754791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 3886
Study 14754791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3886
Study 11348708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepacare (1 month/two dose regimen)
Number of subjects: 400
Study 11348708 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (2 month/three dose regimen)
Number of subjects: 400
Study 9207585 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical contraceptive device (group 1, n = 151)
Number of subjects: 298
Study 9207585 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing fundal contraceptive device (group 2, n = 147)
Number of subjects: 298
Study 8424293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dixyrazine 0.25 mg kg‐1 i.v. after surgery
Number of subjects: 116
Study 8424293 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic dixyrazine
Number of subjects: 116
Study 3326118 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 74
Study 3326118 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 74
Study 3326118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 28913663 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP‐Dads
Number of subjects: 384
Study 28913663 — intervention group
Group type: COMPARATOR
Intervention: Active comparison program
Number of subjects: 384
Study 27141627 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture treatment
Number of subjects: 61
Study 27141627 — intervention group
Group type: COMPARATOR
Intervention: Control group (medication)
Number of subjects: 61
Study 27141627 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Scalp acupuncture and Control)
Number of subjects: 61
Study 24168956 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 1032
Study 24168956 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-monotherapy
Number of subjects: 1032
Study 24168956 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab-continuation
Number of subjects: 1032
Study 24168956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 1032
Study 24168956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 1032
Study 21442416 — intervention group
Group type: EXPERIMENTAL
Intervention: One interim assessment during a small group work session
Number of subjects: 417
Study 21442416 — intervention group
Group type: EXPERIMENTAL
Intervention: Two interim assessments during a small group work session
Number of subjects: 417
Study 21442416 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no interim assessment
Number of subjects: 417
Study 21442416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim assessment on tumour pathology
Number of subjects: 417
Study 21442416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim assessment on topics related to the previous 3 weeks
Number of subjects: 417
Study 21189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle tape applied for lateral ligament sprain in the non-dominant leg
Number of subjects: 40
Study 21189212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ankle tape)
Number of subjects: 40
Study 18179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of thoughts
Number of subjects: 0
Study 15725113 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 15725113 — intervention group
Group type: COMPARATOR
Intervention: Control group (women not offered screening mammography)
Number of subjects: 0
Study 11772479 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement (n=26)
Number of subjects: 48
Study 11772479 — intervention group
Group type: COMPARATOR
Intervention: Attendance reinforcement (n=22)
Number of subjects: 48
Study 10198297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amino acid (MAA) solution (40 g)
Number of subjects: 6
Study 10198297 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid (EAA) solution (40 g)
Number of subjects: 6
Study 10198297 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (PLA)
Number of subjects: 6
Study 7775360 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 to 1.3 mg/kg per day, mean 0.7 mg/kg per day)
Number of subjects: 15
Study 7775360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (1.4 to 5.7 mg/kg per day, mean 3.3 mg/kg per day)
Number of subjects: 15
Study 7775360 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 1692095 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy alone
Number of subjects: 140
Study 1692095 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with radiation
Number of subjects: 140
Study 1692095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiation and chemotherapy
Number of subjects: 140
Study 1692095 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 140
Study 498151 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum (100 mg/m2) administered via rapid infusion (15-minute)
Number of subjects: 0
Study 498151 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum (100 mg/m2) administered via 6-hour infusion
Number of subjects: 0
Study 498151 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum with concomitant administration of mannitol
Number of subjects: 0
Study 498151 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum in patients with renal impairment
Number of subjects: 0
Study 498151 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum
Number of subjects: 0
Study 31215242 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical oral Navelbine (once weekly)
Number of subjects: 0
Study 31215242 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic Navelbine
Number of subjects: 0
Study 28366440 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive learning-based curriculum (PLC)
Number of subjects: 37
Study 28366440 — intervention group
Group type: COMPARATOR
Intervention: Standard comprehensive curriculum (SCC)
Number of subjects: 37
Study 25481364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual examination and ultrasound
Number of subjects: 0
Study 23648613 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental muscle vibration (SMV) combined with general physical therapy
Number of subjects: 44
Study 23648613 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy (Control)
Number of subjects: 44
Study 21177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard feed supplemented with 120 ppm of coumestans from Eclipta alba
Number of subjects: 240
Study 21177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard feed supplemented with 180 ppm of coumestans from Eclipta alba
Number of subjects: 240
Study 21177038 — intervention group
Group type: COMPARATOR
Intervention: Standard feed (negative control)
Number of subjects: 240
Study 21177038 — intervention group
Group type: COMPARATOR
Intervention: Standard feed supplemented with 66 ppm of salinomycin (positive control)
Number of subjects: 240
Study 19957513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment group (serum uric acid level: 249 micromol/L ± 59 micromol/L)
Number of subjects: 104
Study 19957513 — intervention group
Group type: COMPARATOR
Intervention: Non-cognitive impairment group (serum uric acid level: 323 micromol/L ± 52 micromol/L)
Number of subjects: 104
Study 19957513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive scores in PD patients
Number of subjects: 104
Study 17181566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior gestational diabetes (GD)
Number of subjects: 48
Study 17181566 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (control group)
Number of subjects: 48
Study 15794407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Dermatophagoides pteronyssinus (500, 1000, 2000, 5000, 8000, and 10,000 biological units)
Number of subjects: 50
Study 15794407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Dermatophagoides pteronyssinus
Number of subjects: 50
Study 15794407 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 50
Study 11406860 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract (240 mg salicin/day)
Number of subjects: 78
Study 11406860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 11406860 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract
Number of subjects: 78
Study 9835238 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine involvement of a psychiatrist in the assessment and care of medical in-patients with probable psychiatric disorder
Number of subjects: 218
Study 9835238 — intervention group
Group type: COMPARATOR
Intervention: Physicians alone (control group)
Number of subjects: 218
Study 9835238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians informed of screening results
Number of subjects: 218
Study 9835238 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments recommended by psychiatrists
Number of subjects: 218
Study 7851375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot environment (Ta 36.7 +/‐ 0.2 degree C, rh 46.1 +/‐ 3.2%)
Number of subjects: 6
Study 7851375 — intervention group
Group type: COMPARATOR
Intervention: Neutral environment (Ta 19.6 +/‐ 0.3 degree C, rh 50.2 +/‐ 1.4%)
Number of subjects: 6
Study 2670536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653 (phenytoin prodrug) intravenous administration
Number of subjects: 0
Study 2670536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653 (phenytoin prodrug) intramuscular administration
Number of subjects: 0
Study 2670536 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenytoin intravenous administration
Number of subjects: 0
Study 412590 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 rads of megavoltage irradiation to the site of the lesion given as a single dose and repeated 7 days later
Number of subjects: 20
Study 412590 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated lesions
Number of subjects: 20
Study 412590 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated lesions
Number of subjects: 20
Study 30500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg once weekly
Number of subjects: 309
Study 30500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 70 mg thrice weekly
Number of subjects: 309
Study 30500603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 30173291 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted TAP block with 30 ml 0.25% Bupivacaine
Number of subjects: 60
Study 30173291 — intervention group
Group type: COMPARATOR
Intervention: Periportal local anaesthetic infiltration with 15 ml of 0.5% Bupivacaine
Number of subjects: 60
Study 27094918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral bioanalytical method for R‐ibuprofen and S‐ibuprofen
Number of subjects: 0
Study 27094918 — intervention group
Group type: COMPARATOR
Intervention: Achiral bioanalytical method
Number of subjects: 0
Study 24612455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day for at least 3 months (Group 1)
Number of subjects: 102
Study 24612455 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 102
Study 24612455 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls (Group 3)
Number of subjects: 102
Study 22275272 — intervention group
Group type: EXPERIMENTAL
Intervention: [phenyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Number of subjects: 12
Study 22275272 — intervention group
Group type: EXPERIMENTAL
Intervention: [glycolyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Number of subjects: 12
Study 22275272 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessment
Number of subjects: 12
Study 20370474 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) taken on awakening
Number of subjects: 316
Study 20370474 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) taken at bedtime
Number of subjects: 316
Study 17645592 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg)
Number of subjects: 90
Study 17645592 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)
Number of subjects: 90
Study 17645592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (40 mg) alone
Number of subjects: 90
Study 17645592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16030154 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg levonorgestrel (LNG) daily, orally
Number of subjects: 29
Study 16030154 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 0.5 mg dutasteride daily, orally
Number of subjects: 29
Study 16030154 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 300 microg/kg acyline twice weekly, s.c.
Number of subjects: 29
Study 16030154 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 300 microg/kg acyline twice weekly, s.c.
Number of subjects: 29
Study 16030154 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 29
Study 12871685 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (1mg/Kg bolus and 1mg/Kg/h continuous IV drip for 5h)
Number of subjects: 30
Study 12871685 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 30
Study 10348763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in dextrose (78 courses)
Number of subjects: 82
Study 10348763 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B in lipid emulsion (84 courses)
Number of subjects: 82
Study 10348763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in dextrose
Number of subjects: 82
Study 10348763 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B in lipid emulsion
Number of subjects: 82
Study 8605328 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (5 microg/kg/d subcutaneously)
Number of subjects: 34
Study 8605328 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 34
Study 8605328 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF
Number of subjects: 34
Study 2010788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabao (Chinese herb extract)
Number of subjects: 396
Study 2010788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 7035031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with killed armadillo-derived M. leprae
Number of subjects: 0
Study 7035031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with killed M. leprae in a mixture with live BCG
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg kg‐1
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.5 mg kg‐1 (preceded by gallamine 20 mg 2 min earlier)
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 to 0.2 mg kg‐1
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 6147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 31688392 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 pharmacogenetic screening (DG-I)
Number of subjects: 0
Study 31688392 — intervention group
Group type: COMPARATOR
Intervention: Deviating genotype control arm (DG-C)
Number of subjects: 0
Study 30305174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral emotion regulation module (in different sequences)
Number of subjects: 0
Study 30305174 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 27261988 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddhist walking meditation (WM)
Number of subjects: 23
Study 27261988 — intervention group
Group type: COMPARATOR
Intervention: Traditional walking exercise (WE)
Number of subjects: 23
Study 23669820 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet pulse stimulus
Number of subjects: 12
Study 23669820 — intervention group
Group type: EXPERIMENTAL
Intervention: Central activation ratio calculation method
Number of subjects: 12
Study 23669820 — intervention group
Group type: COMPARATOR
Intervention: 10-pulse train of stimuli
Number of subjects: 12
Study 21883820 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 31
Study 21883820 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 31
Study 20092835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac loaded stent
Number of subjects: 276
Study 20092835 — intervention group
Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 276
Study 17586711 — intervention group
Group type: EXPERIMENTAL
Intervention: One-minute intervention consisting of forming a concrete plan of where, when, and how to floss.
Number of subjects: 239
Study 17586711 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a packet of floss, information, and a flossing guide without the planning intervention).
Number of subjects: 239
Study 15615737 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations video group
Number of subjects: 141
Study 15615737 — intervention group
Group type: COMPARATOR
Intervention: Anatomy video group
Number of subjects: 141
Study 15615737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 15615737 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous cataract surgery experience
Number of subjects: 141